Radiation modifiers: Treatment overview and future investigations

Hematology/Oncology Clinics of North America

Volumn 20, Issue 1, 2006, Pages 119-139

  Thomas, C T ^a   Ammar, A ^b   Farrell, J J ^a   Elsaleh, H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ASCORBIC ACID; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETANIDAZOLE; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MEVINOLIN; MISONIDAZOLE; NIMORAZOLE; OXALIPLATIN; PACLITAXEL; PENTOXIFYLLINE; PILOCARPINE; SUCRALFATE; TIRAPAZAMINE; TOCOPHEROL;

ALLERGIC REACTION; ANXIETY DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CACHEXIA; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DROWSINESS; ERYTHEMA; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERSALIVATION; HYPERTHERMIA; HYPOTENSION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; STOMATITIS; VOMITING; WEAKNESS;

HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 33645416090     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.01.012     Document Type: Review

References (224)

1. E.J. Hall Radiosensitizers and bioreductive drugs. In: Radiobiology for the radiologist 4th edition 1994 Lippincott, Williams & Wilkins 165 182
2. E.M.A. Chu, and M.C. Fogarasi Antimetabolites Cancer: principles and practice of oncology 6th edition 2001 Lippincott, Williams & Wilkins
3. D.V. Santi, C.S. McHenry, and R.T. Raines Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase Biochemistry 26 1987 8606 8613
4. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer J Clin Oncol 16 1998 301 308
5. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer J Clin Oncol 16 1998 3537 3541
6. P.M. Hoff, J. Cassidy, and H.J. Schmoll The evolution of fluoropyrimidine therapy: from intravenous to oral Oncologist 6 Suppl 4 2001 3 11
7. G. Liu, E. Franssen, and M.I. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
8. M. Borner, W. Scheithauer, and C. Twelves Answering patients' needs: oral alternatives to intravenous therapy Oncologist 6 Suppl 4 2001 12 16
9. M.M. Borner, P. Schoffski, and R. de Wit Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 2002 349 358
10. S. Marsh, E.S. Collie-Duguid, and T. Li Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations Genomics 58 1999 310 312
11. B. Iacopetta, F. Grieu, and D. Joseph A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil Br J Cancer 85 2001 827 830
12. A. Herskovic, L. Leichman, and P. Lattin Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience Int J Radiat Oncol Biol Phys 15 1988 655 662
13. T. Toita, K. Ogawa, and G. Adachi Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high-dose external beam boost irradiation Jpn J Clin Oncol 31 2001 375 381
14. J.F. Seitz, C. Milan, and M. Giovannini [Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)] Gastroenterol Clin Biol 24 2000 201 210 [in French]
15. J.E. Byfield, R. Barone, and J. Mendelsohn Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer Cancer 45 1980 703 708
16. B.H. Burmeister, G. Dickie, and B.M. Smithers Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy Arch Otolaryngol Head Neck Surg 126 2000 205 208
17. L.R. Coia Chemoradiation: a superior alternative for the primary management of esophageal carcinoma Semin Radiat Oncol 4 1994 157 164
18. L.R. Coia, B.D. Minsky, and M.J. John The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study Cancer 85 1999 2499 2505
19. A. Herskovic, K. Martz, and M. al-Sarraf Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1992 1593 1598
20. T.J. Smith, L.M. Ryan, and H.O. Douglass Jr Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group Int J Radiat Oncol Biol Phys 42 1998 269 276
21. J.S. Cooper, M.D. Guo, and A. Herskovic Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group JAMA 281 1999 1623 1627
22. M. Flam, M. John, and T.F. Pajak Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 14 1996 2527 2539
23. B.J. Cummings The role of radiation therapy with 5-fluorouracil in anal cancer Semin Radiat Oncol 7 1997 306 312
24. C.H. Crane, J.M. Skibber, and B.W. Feig Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma Cancer 97 2003 517 524
25. Rich T.A. Infusional chemoradiation for operable rectal cancer: post-, pre-, or nonoperative management? Oncology 1997;11:295-300, 305
26. M.J. O'Connell, J.A. Martenson, and H.S. Wieand Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery N Engl J Med 331 1994 502 507
27. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group N Engl J Med 312 1985 1465 1472
28. J.E. Krook, C.G. Moertel, and L.L. Gunderson Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 1991 709 715
29. T.A. Rich, J.M. Skibber, and J.A. Ajani Preoperative infusional chemoradiation therapy for stage T3 rectal cancer Int J Radiat Oncol Biol Phys 32 1995 1025 1029
30. T.C. Lo, A.L. Wiley Jr, and F.J. Ansfield Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study AJR Am J Roentgenol 126 1976 229 235
31. G.P. Browman, C. Cripps, and D.I. Hodson Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer J Clin Oncol 12 1994 2648 2653
32. I.N. Olver, P.G. Hughes, and J.G. Smith Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer Eur J Cancer 32A 1996 249 254
33. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
34. D.J. Adelstein, J.P. Saxton, and P. Lavertu Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy J Clin Oncol 20 2002 1405 1410
35. D.J. Adelstein, P. Lavertu, and J.P. Saxton Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck Cancer 88 2000 876 883
36. V. Magnin, V. Moutardier, and M.H. Giovannini Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer Int J Radiat Oncol Biol Phys 55 2003 1300 1304
37. J. Aristu, R. Canon, and F. Pardo Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer Am J Clin Oncol 26 2003 30 36
38. S. Mawdsley, M. Hall, and R. Glynne-Jones Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil Clin Oncol (R Coll Radiol) 14 2002 308 312
39. H. Shinchi, S. Takao, and H. Noma Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 53 2002 146 150
40. J.P. Arnoletti, J.P. Hoffman, and E.A. Ross Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas Am Surg 68 2002 330 335 [discussion: 335-6]
41. V.K. Mehta, J.C. Poen, and J.M. Ford Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer Am J Clin Oncol 24 2001 155 159
42. G. Boz, A. De Paoli, and R. Innocente Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma Int J Radiat Oncol Biol Phys 51 2001 736 740
43. V.K. Mehta, G.A. Fisher, and J.M. Ford Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer Int J Radiat Oncol Biol Phys 48 2000 1483 1487
44. A. Chakravarthy, R.A. Abrams, and C.J. Yeo Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival Int J Radiat Oncol Biol Phys 48 2000 1089 1096
45. R.A. Abrams, L.B. Grochow, and A. Chakravarthy Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels Int J Radiat Oncol Biol Phys 44 1999 1039 1046
46. R. Pearcey, M. Brundage, and P. Drouin Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix J Clin Oncol 20 2002 966 972
47. H.M. Keys, B.N. Bundy, and F.B. Stehman Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
48. L.C. Wong, H.Y. Ngan, and A.N. Cheung Chemoradiation and adjuvant chemotherapy in cervical cancer J Clin Oncol 17 1999 2055 2060
49. W.A. Peters III, P.Y. Liu, and R.J. Barrett II Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 2000 1606 1613
50. P.G. Rose, B.N. Bundy, and E.B. Watkins Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
51. M. Morris, P.J. Eifel, and J. Lu Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143
52. S.A. Hundahl, J.L. Phillips, and H.R. Menck The National Cancer Data Base report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer Staging, Proximal Disease, and the "Different Disease" Hypothesis Cancer 88 2000 921 932
53. E. Gez, A. Sulkes, and T. Yablonsky-Peretz Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma J Surg Oncol 31 1986 139 142
54. L.L. Gunderson, R.B. Hoskins, and A.C. Cohen Combined modality treatment of gastric cancer Int J Radiat Oncol Biol Phys 9 1983 965 975
55. R. Martinez Monge, M. Jurado, and I. Azinovic Preoperative chemoradiation and adjuvant surgery in locally advanced or recurrent cervical carcinoma Rev Med Univ Navarra 41 1997 19 26
56. J.S. Macdonald, S.R. Smalley, and J. Benedetti Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
57. B. Paule, and F. Saint [Simultaneous chemotherapy/radiotherapy in locally advanced unresectable cancer of the bladder] Prog Urol 11 2001 132 140 [in French]
58. M. Rotman, H. Aziz, and M. Porrazzo Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion Int J Radiat Oncol Biol Phys 18 1990 1131 1137
59. K.J. Russell, M.A. Boileau, and C. Higano Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder Int J Radiat Oncol Biol Phys 19 1990 693 699
60. F.M. Serafini, D. Sachs, and M. Bloomston Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy Am Surg 67 2001 839 843 [discussion: 843-4]
61. A. Nakeeb, K.Q. Tran, and M.J. Black Improved survival in resected biliary malignancies Surgery 132 2002 555 563 [discussion: 563-4]
62. L.L. Hughes, J. Luengas, and T.A. Rich Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery Int J Radiat Oncol Biol Phys 23 1992 983 991
63. N. Sawada, T. Ishikawa, and F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
64. M. Miwa, M. Ura, and M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
65. J. Schuller, J. Cassidy, and E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
66. J.S. Kovach, and R.W. Beart Jr Cellular pharmacology of fluorinated pyrimidines in vivo in man Invest New Drugs 7 1989 13 25
67. E.B. Lamont, and R.L. Schilsky The oral fluoropyrimidines in cancer chemotherapy Clin Cancer Res 5 1999 2289 2296
68. C. Twelves, M. Boyer, and M. Findlay Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma Eur J Cancer 37 2001 597 604
69. J.Y. Pierga, P. Fumoleau, and Y. Brewer Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program Breast Cancer Res Treat 88 2004 117 129
70. J. Feliu, P. Escudero, and F. Llosa Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz cooperative group study J Clin Oncol 23 2005 3104 3111
71. C.M. Walko, and C. Lindley Capecitabine: a review Clin Ther 27 2005 23 44
72. J. Dunst, T. Reese, and T. Sutter Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer J Clin Oncol 20 2002 3983 3991
73. C. Rodel, G.G. Grabenbauer, and T. Papadopoulos Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer J Clin Oncol 21 2003 3098 3104
74. C.M. Sorenson, M.A. Barry, and A. Eastman Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin J Natl Cancer Inst 82 1990 749 755
75. R.C. Richmond Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells Radiat Res 99 1984 596 608
76. G.P. Amorino, M.L. Freeman, and D.P. Carbone Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition Int J Radiat Oncol Biol Phys 44 1999 399 405
77. L.X. Yang, E.B. Douple, and H.J. Wang Irradiation enhances cellular uptake of carboplatin Int J Radiat Oncol Biol Phys 33 1995 641 646
78. T. Servidei, C. Ferlini, and A. Riccardi The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin Eur J Cancer 37 2001 930 938
79. L.K. Kvols Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets J Nucl Med 46 Suppl 1 2005 187S 190S
80. P.J. Loehrer, and L.H. Einhorn Drugs five years later. Cisplatin Ann Intern Med 100 1984 704 713
81. J.M. Extra, M. Espie, and F. Calvo Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother Pharmacol 25 1990 299 303
82. D. Machover, E. Diaz-Rubio, and A. de Gramont Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 1996 95 98
83. A.T. Turrisi III, K. Kim, and R. Blum Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 340 1999 265 271
84. G.S. Gordon, and E.E. Vokes Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies Oncology (Williston Park) 13 1999 1075 1088 [discussion: 1088, 1091-4]
85. K.S. Albain, J.J. Crowley, and A.T. Turrisi III Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019 J Clin Oncol 20 2002 3454 3460
86. G.P. Browman, D.I. Hodson, and R.J. Mackenzie Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis Head Neck 23 2001 579 589
87. C. Aschele, M.L. Friso, and S. Pucciarelli A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer Ann Oncol 16 2005 1140 1146
88. G. Freyer, N. Bossard, and P. Romestaing Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial J Clin Oncol 19 2001 2433 2438
89. J.P. Gerard, O. Chapet, and C. Nemoz Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial J Clin Oncol 21 2003 1119 1124
90. P. Huang, S. Chubb, and L.W. Hertel Action of 2′,2′- difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
91. D.D. Ross, and D.P. Cuddy Molecular effects of 2′,2′- difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells Biochem Pharmacol 48 1994 1619 1630
92. D.S. Shewach, T.M. Hahn, and E. Chang Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res 54 1994 3218 3223
93. D. Latz, K. Fleckenstein, and M. Eble Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro Int J Radiat Oncol Biol Phys 41 1998 875 882
94. R.A. Wolff, D.B. Evans, and D.M. Gravel Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma Clin Cancer Res 7 2001 2246 2253
95. M.S. Talamonti, P.J. Catalano, and D.J. Vaughn Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity J Clin Oncol 18 2000 3384 3389
96. C.G. Willett, H. Safran, and R.A. Abrams Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials Int J Radiat Oncol Biol Phys 56 2003 31 37
97. M.L. Rothenberg, M.J. Moore, and M.C. Cripps A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 1996 347 353
98. S.G. Divers, S.A. Spencer, and D. Carey Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer J Clin Oncol 23 2005 6664 6673
99. V.K. Sangar, C.A. McBain, and J. Lyons Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer Int J Radiat Oncol Biol Phys 61 2005 420 425
100. C. Rodel Current status of radiation therapy and combined-modality treatment for bladder cancer Strahlentherapie und Onkologie 180 2004 701 709
101. L. Milas, K. Kishi, and N. Hunter Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme J Natl Cancer Inst 91 1999 1501 1504
102. K.A. Mason Radiation interactions with taxanes, old and new Radiat Res 163 2005 705 706
103. L. Milas, K.A. Mason, and N. Hunter Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability Int J Radiat Oncol Biol Phys 55 2003 707 712
104. H. Choy Taxanes in combined modality therapy for solid tumors Crit Rev Oncol Hematol 37 2001 237 247
105. T.A. Rich, and A.V. Kirichenko Camptothecin radiation sensitization: mechanisms, schedules, and timing Oncology (Williston Park) 12 1998 114 120
106. A.Y. Chen, H. Choy, and M.L. Rothenberg DNA topoisomerase I-targeting drugs as radiation sensitizers Oncology (Williston Park) 13 1999 39 46
107. K. Tamura, M. Takada, and I. Kawase Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts Jpn J Cancer Res 88 1997 218 223
108. D.S. Wang, Y. Ueno, and H. Oyamada Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma Biol Pharm Bull 19 1996 354 359
109. C. Hennequin, N. Giocanti, and J. Balosso Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells Cancer Res 54 1994 1720 1728
110. R.E. Boscia, T. Korbut, and S.A. Holden Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo Int J Cancer 53 1993 118 123
111. A.X. Zhu, and C.G. Willett Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer Semin Radiat Oncol 13 2003 454 468
112. R.D. Hofheinz, B. von Gerstenberg-Helldorf, and F. Wenz Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer J Clin Oncol 23 2005 1350 1357
113. D.H. Ilson, M. Bains, and D.P. Kelsen Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer J Clin Oncol 21 2003 2926 2932
114. K. Kishi, S. Petersen, and C. Petersen Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Res 60 2000 1326 1331
115. D.H. Gorski, H.J. Mauceri, and R.M. Salloum Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin Cancer Res 58 1998 5686 5689
116. H.J. Mauceri, N.N. Hanna, and M.A. Beckett Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
117. US Food and Drug Administration Available at: http://www.fda.gov/cder/ drug/infopage/cox2/default.htm
118. E.J. Hall The oxygen effect and reoxygenation Radiobiology for the radiologist 4th edition 1994 Lippincott, Williams & Wilkins 133 152
119. J. Overgaard, J.G. Erikson, M. Nordsmark The Danish Head and Neck Cancer Study Group Plasma osteopontin, hypoxia and response to hypoxic sensitiser nimorazole in radiotherapy of head and neck cancer: Results of DAHANCA 5 randomized double-blind placebo-controlled trial Lancet Oncol 6 10 2005 757 764 [Epub 2005 Aug 27]
120. J. Overgaard, and M.R. Horsman Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers Semin Radiat Oncol 6 1996 10 21
121. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509 518
122. J.M. Brown, and W.R. Wilson Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 2004 437 447
123. J.H. Kaanders, J. Bussink, and A.J. van der Kogel Clinical studies of hypoxia modification in radiotherapy Semin Radiat Oncol 14 2004 233 240
124. P. Stadler, H.J. Feldmann, and C. Creighton Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer Radiother Oncol 48 1998 157 164
125. M.J. Boyer Bioreductive agents: a clinical update Oncol Res 9 1997 391 395
126. R.L. Cowen, K.J. Williams, and E.C. Chinje Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure Cancer Res 64 2004 1396 1402
127. B.G. Siim, F.B. Pruijn, and J.R. Sturman Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317 Cancer Res 64 2004 736 742
128. S.V. Kozin, Y. Boucher, and D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
129. K.J. Kim, B. Li, and J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
130. D. Shweiki, A. Itin, and D. Soffer Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 845
131. J. Li, S. Huang, and E.A. Armstrong Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade Int J Radiat Oncol Biol Phys 62 2005 1477 1485
132. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
133. T.J. FitzGerald, C. Daugherty, and K. Kase Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation Am J Clin Oncol 8 1985 517 522
134. M.D. Sklar The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation Science 239 1988 645 647
135. C.C. Ling, and B. Endlich Radioresistance induced by oncogenic transformation Radiat Res 120 1989 267 279
136. W.G. McKenna, M.C. Weiss, and V.J. Bakanauskas The role of the H-ras oncogene in radiation resistance and metastasis Int J Radiat Oncol Biol Phys 18 1990 849 859
137. W.G. McKenna, M.C. Weiss, and B. Endlich Synergistic effect of the v-myc oncogene with H-ras on radioresistance Cancer Res 50 1990 97 102
138. S.L. McKenna, and T.G. Cotter Functional aspects of apoptosis in hematopoiesis and consequences of failure Adv Cancer Res 71 1997 121 164
139. E.J. Bernhard, G. Kao, and A.D. Cox The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Res 56 1996 1727 1730
140. A.C. Miller, K. Kariko, and C.E. Myers Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation Int J Cancer 53 1993 302 307
141. T.B. Brunner, S.M. Hahn, and W.G. McKenna Radiation sensitization by inhibition of activated Ras Strahlentherapie und Onkologie 180 2004 731 740
142. J.S. Russell, F.F. Lang, and T. Huet Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment Cancer Res 59 1999 5239 5244
143. M.T. Sheridan, T. O'Dwyer, and C.B. Seymour Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Investig 5 1997 180 186
144. P.M. Harari, and S.M. Huang Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development Semin Radiat Oncol 12 2002 21 26
145. B. Solomon, J. Hagekyriakou, and M.K. Trivett EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor Int J Radiat Oncol Biol Phys 55 2003 713 723
146. L. Sartor Epidermal growth factor family receptors and inhibitors: radiation response modulators Semin Radiat Oncol 1 2003 22 30
147. L. Milas, K. Mason, and N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
148. J. Harding, and B. Burtness Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody Drugs Today (Barc) 41 2005 107 127
149. J.E. Head, and S.R. Johnston Protein farnesyltransferase inhibitors Expert Opin Emerg Drugs 8 2003 163 178
150. E. Jabbour, H. Kantarjian, and J. Cortes Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action Leuk Lymphoma 45 2004 2187 2195
151. G.P. Prevost, A. Pradines, and M.C. Brezak Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228 Int J Cancer 91 2001 718 722
152. R. Datta, E. Rubin, and V. Sukhatme Ionizing radiation activates transcription of the EGR1 gene via CArG elements Proc Natl Acad Sci USA 89 1992 10149 10153
153. D.E. Hallahan, H.J. Mauceri, and L.P. Seung Spatial and temporal control of gene therapy using ionizing radiation Nat Med 1 1995 786 791
154. L.P. Seung, H.J. Mauceri, and M.A. Beckett Genetic radiotherapy overcomes tumor resistance to cytotoxic agents Cancer Res 55 1995 5561 5565
155. R.R. Weichselbaum, D.W. Kufe, and S. Hellman Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy Lancet Oncol 3 2002 665 671
156. F.R. Balkwill, B.G. Ward, and E. Moodie Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer Cancer Res 47 1987 4755 4758
157. A. Asher, J.J. Mule, and C.M. Reichert Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo J Immunol 138 1987 963 974
158. A.A. Creasey, M.T. Reynolds, and W. Laird Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor Cancer Res 46 1986 5687 5690
159. D. Fukumura, H.A. Salehi, and B. Witwer Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain Cancer Res 55 1995 4824 4829
160. H.J. Mauceri, N.N. Hanna, and J.D. Wayne Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature Cancer Res 56 1996 4311 4314
161. T.D. Chung, H.J. Mauceri, and D.E. Hallahan Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer Cancer Gene Ther 5 1998 344 349
162. M.J. Staba, H.J. Mauceri, and D.W. Kufe Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft Gene Ther 5 1998 293 300
163. V.K. Gupta, J.O. Park, and N.T. Jaskowiak Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma Ann Surg Oncol 9 2002 500 504
164. D.E. Hallahan, E.E. Vokes, and S.J. Rubin Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy Cancer J Sci Am 1 1995 204
165. R.A. Marr, M. Hitt, and J. Gauldie A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity Cancer Gene Ther 6 1999 465 4674
166. R.A. Marr, M. Hitt, and W.J. Muller Tumour therapy in mice using adenovirus vectors expressing human TNFa Int J Oncol 12 1998 509 515
167. A.J. Mundt, S. Vijayakumar, and J. Nemunaitis A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities Clin Cancer Res 10 2004 5747 5753
168. H. Gamm, A. Lindemann, and R. Mertelsmann Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy Eur J Cancer 27 1991 856 863
169. N. Senzer, S. Mani, and A. Rosemurgy TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors J Clin Oncol 22 2004 592 601
170. J.M. McLoughlin, T.M. McCarty, and C. Cunningham TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up Ann Surg Oncol 12 2005 825 830
171. E.J. Hall Hyperthermia Radiobiology for the radiologist 4th edition 1994 Lippincott, Williams & Wilkins 257 288
172. J.R. Lepock Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage Int J Hyperthermia 19 2003 252 266
173. J.A. Koutcher, D. Barnett, and A.B. Kornblith Relationship of changes in pH and energy status to hypoxic cell fraction and hyperthermia sensitivity Int J Radiat Oncol Biol Phys 18 1990 1429 1435
174. K. Engin, D.B. Leeper, and A.J. Thistlethwaite Tumor extracellular pH as a prognostic factor in thermoradiotherapy Int J Radiat Oncol Biol Phys 29 1994 125 132
175. P.K. Sneed, and T.L. Phillips Combining hyperthermia and radiation: how beneficial? Oncology (Williston Park) 5 1991 99 108 [discussion: 109-10, 112]
176. C.C. Vernon, J.W. Hand, and S.B. Field Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group Int J Radiat Oncol Biol Phys 35 1996 731 744
177. J. Overgaard, D. Gonzalez Gonzalez, and M.C. Hulshof Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology Lancet 345 1995 540 543
178. R. Valdagni, and M. Amichetti Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients Int J Radiat Oncol Biol Phys 28 1994 163 169
179. N.R. Datta, A.K. Bose, and H.K. Kapoor Head and neck cancers: results of thermoradiotherapy versus radiotherapy Int J Hyperthermia 6 1990 479 486
180. J. van der Zee, D. Gonzalez Gonzalez, and G.C. van Rhoon Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group Lancet 355 2000 1119 1125
181. Y. Harima, K. Nagata, and K. Harima A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma Int J Hyperthermia 17 2001 97 105
182. S. Sharma, A.P. Sandhu, and F.D. Patel Side-effects of local hyperthermia: results of a prospectively randomized clinical study Int J Hyperthermia 6 1990 279 285
183. P.K. Sneed, P.R. Stauffer, and M.W. McDermott Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ±hyperthermia for glioblastoma multiforme Int J Radiat Oncol Biol Phys 40 1998 287 295
184. E.L. Jones, J.R. Oleson, and L.R. Prosnitz Randomized trial of hyperthermia and radiation for superficial tumors J Clin Oncol 23 2005 3079 3085
185. M. Urano Kinetics of thermotolerance in normal and tumor tissues: a review Cancer Res 46 1986 474 482
186. D.M. Brizel, T.H. Wasserman, and M. Henke Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 18 2000 3339 3345
187. M.I. Koukourakis Amifostine: is there evidence of tumor protection? Semin Oncol 30 2003 18 30
188. S. McDonald, C. Meyerowitz, and T. Smudzin Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction Int J Radiat Oncol Biol Phys 29 1994 747 754
189. K.G. Schonekas, W. Wagner, and F.J. Prott Amifostine-a radioprotector in locally advanced head and neck tumors Strahlentherapie und Onkologie 175 Suppl 4 1999 27 29
190. D. Antonadou, M. Pepelassi, and M. Synodinou Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int J Radiat Oncol Biol Phys 52 2002 739 747
191. C.E. Saadeh Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment Pharmacotherapy 25 2005 540 554
192. M. Elas, A. Parasca, and D.J. Grdina Oral administration is as effective as intraperitoneal administration of amifostine in decreasing nitroxide EPR signal decay in vivo Biochim Biophys Acta 1637 2003 151 155
193. E. Bardet, L. Martin, and G. Calais Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy Semin Oncol 29 2002 57 60
194. P.R. Anne Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer Semin Oncol 29 2002 80 83
195. V.E. Kouloulias, J.R. Kouvaris, and G. Pissakas Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application Int J Radiat Oncol Biol Phys 62 2005 486 493
196. E. Ben-Josef, S. Han, and M. Tobi A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury Int J Radiat Oncol Biol Phys 53 2002 1160 1164
197. V.E. Kouloulias, J.R. Kouvaris, and G. Pissakas A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity Strahlentherapie und Onkologie 180 2004 557 562
198. C. Menard, K. Camphausen, and T. Muanza Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results Semin Oncol 30 2003 63 67
199. V.E. Kouloulias, J.R. Kouvaris, and J.D. Kokakis Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis Int J Radiat Oncol Biol Phys 59 2004 1148 1156
200. F.Y. De Vos, A.M. Bos, and M. Schaapveld A randomized phase II study of paclitaxel with carboplatin ±amifostine as first line treatment in advanced ovarian carcinoma Gynecol Oncol 97 2005 60 67
201. B.L. Slomiany, J. Piotrowski, and K. Okazaki Nature of the enhancement of the protective qualities of gastric mucus by sucralfate Digestion 44 1989 222 231
202. W.D. Rees Mechanisms of gastroduodenal protection by sucralfate Am J Med 91 1991 58S 63S
203. J. Garcia-Paredes, M. Diaz Rubio, and F. Llenas Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers Am J Med 91 1991 64S 67S
204. K. Saarilahti, M. Kajanti, and T. Joensuu Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study Int J Radiat Oncol Biol Phys 54 2002 479 485
205. R. Henriksson, L. Franzen, and B. Littbrand Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer J Clin Oncol 10 1992 969 975
206. R. Henriksson, L. Franzen, and B. Littbrand Prevention and therapy of radiation-induced bowel discomfort Scand J Gastroenterol Suppl 191 1992 7 11
207. P.C. O'Brien, C.I. Franklin, and M.G. Poulsen Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial-Trans-Tasman Radiation Oncology Group Int J Radiat Oncol Biol Phys 54 2002 442 449
208. J.A. Martenson, J.W. Bollinger, and J.A. Sloan Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial J Clin Oncol 18 2000 1239 1245
209. G.C. Jagetia, G.K. Rajanikant, and M.S. Baliga Augmentation of wound healing by ascorbic acid treatment in mice exposed to gamma-radiation Int J Radiat Biol 80 2004 347 354
210. L. Gothard, P. Cornes, and S. Brooker Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy Radiother Oncol 75 2005 334 341
211. V.R. Narra, R.W. Howell, and K.S. Sastry Vitamin C as a radioprotector against iodine-131 in vivo J Nucl Med 34 1993 637 640
212. F. Cetta, M.C. Curia, and G. Montalto Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene J Clin Endocrinol Metab 86 2001 427 432
213. N. Cherdyntseva, A. Shishkina, and I. Butorin Effect of tocopherol-monoglucoside (TMG), a water-soluble glycosylated derivate of vitamin E, on hematopoietic recovery in irradiated mice J Radiat Res (Tokyo) 46 2005 37 41
214. H. Letur-Konirsch, F. Guis, and S. Delanian Uterine restoration by radiation sequelae regression with combined pentoxifylline-tocopherol: a phase II study Fertil Steril 77 2002 1219 1226
215. S. Delanian, R. Porcher, and S. Balla-Mekias Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis J Clin Oncol 21 2003 2545 2550
216. I. Bairati, F. Meyer, and M. Gelinas Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients J Clin Oncol 23 2005 5805 5813
217. O.I. Shadyro, A.A. Sosnovskaya, and I.P. Edimecheva Effects of various vitamins and coenzymes Q on reactions involving alpha-hydroxyl-containing radicals Free Radic Res 39 2005 713 718
218. D.E. Schuller, P. Stevens, and K.P. Clausen Treatment of radiation side effects with oral pilocarpine J Surg Oncol 42 1989 272 276
219. F.G. LeVeque, M. Montgomery, and D. Potter A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients J Clin Oncol 11 1993 1124 1131
220. P. Haddad, and M. Karimi A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia Radiother Oncol 64 2002 29 32
221. J.W. Rieke, M.D. Hafermann, and J.T. Johnson Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials Int J Radiat Oncol Biol Phys 31 1995 661 669
222. P. Warde, B. O'Sullivan, and J. Aslanidis A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer Int J Radiat Oncol Biol Phys 54 2002 9 13
223. M. Gornitsky, G. Shenouda, and K. Sultanem Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 2004 45 52
224. J. Fisher, C. Scott, and C.W. Scarantino Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09 Int J Radiat Oncol Biol Phys 56 2003 832 836